A detailed history of Parallel Advisors, LLC transactions in Evotec Se stock. As of the latest transaction made, Parallel Advisors, LLC holds 174 shares of EVO stock, worth $777. This represents 0.0% of its overall portfolio holdings.

Number of Shares
174
Previous 1,540 88.7%
Holding current value
$777
Previous $7,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.96 - $5.34 $4,043 - $7,294
-1,366 Reduced 88.7%
174 $0
Q2 2024

Aug 08, 2024

BUY
$4.07 - $7.87 $5,982 - $11,568
1,470 Added 2100.0%
1,540 $7,000
Q4 2022

Feb 03, 2023

SELL
$7.8 - $9.85 $1,138 - $1,438
-146 Reduced 67.59%
70 $0
Q3 2022

Nov 10, 2022

BUY
$8.4 - $28.4 $1,024 - $3,464
122 Added 129.79%
216 $2,000
Q2 2022

Aug 01, 2022

SELL
$10.78 - $15.5 $1,617 - $2,325
-150 Reduced 61.48%
94 $1,000
Q1 2022

Apr 28, 2022

BUY
$12.93 - $23.46 $3,154 - $5,724
244 New
244 $4,000

Others Institutions Holding EVO

About Evotec SE


  • Ticker EVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 353,904,992
  • Market Cap $1.58B
  • Description
  • Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare di...
More about EVO
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.